Patents by Inventor Jonathan Karn
Jonathan Karn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11624095Abstract: A method of determining the latent HIV reservoir level in a subject includes obtaining a blood sample from an HIV+ subject, isolating CD4+ T cells from the biological sample, administering one or more HIV transcription inducing agents to the isolated CD4+ T cells, isolating RNA from the CD4+ T-cells that includes HIV env mRNA, producing a plurality of first amplicons from the from the isolated RNA using a first primer set that corresponds to an HIV genomic region encoding the HIV env protein, producing a plurality of second amplicons from the plurality of first amplicons using a second primer set, the second primer set including one or more adapter sequences and/or uniquely identifiable barcode sequences, and determining the nucleic acid sequences of the second amplicons, wherein the determined nucleic acid sequences in the sample are indicative of the amount of inducible cell-associated HIV env RNA in the sample and indicative of the latent HIV reservoir in the subject.Type: GrantFiled: September 27, 2018Date of Patent: April 11, 2023Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Jonathan Karn, Miguel Quinones-Mateu, Curtis Dobrowolski
-
Publication number: 20190093182Abstract: A method of determining the latent HIV reservoir level in a subject includes obtaining a blood sample from an HIV+ subject, isolating CD4+ T cells from the biological sample, administering one or more HIV transcription inducing agents to the isolated CD4+ T cells, isolating RNA from the CD4+ T-cells that includes HIV env mRNA, producing a plurality of first amplicons from the from the isolated RNA using a first primer set that corresponds to an HIV genomic region encoding the HIV env protein, producing a plurality of second amplicons from the plurality of first amplicons using a second primer set, the second primer set including one or more adapter sequences and/or uniquely identifiable barcode sequences, and determining the nucleic acid sequences of the second amplicons, wherein the determined nucleic acid sequences in the sample are indicative of the amount of inducible cell-associated HIV env RNA in the sample and indicative of the latent HIV reservoir in the subject.Type: ApplicationFiled: September 27, 2018Publication date: March 28, 2019Inventors: Jonathan Karn, Miguel Quinones-Mateu, Curtis Dombrowolski
-
Publication number: 20160143917Abstract: A pharmaceutical composition for inducing reactivation of latent provirus in an HIV infected cell includes an ESR-1 antagonist or an ESR-1 coactivator antagonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 29, 2014Publication date: May 26, 2016Inventors: Jonathan Karn, Biswajit Das
-
Patent number: 6946249Abstract: The present invention describes a novel nucleic acid sequencing reagent which consists of a capture moiety, a spacer region and a sequence specific hybridizing region of 4-8 bases. The nucleic acid sequencing reagent of the present invention can also contain an attachment moiety. The nucleic acid sequencing reagent can be arranged into a nested array. This array configuration can then be used to sequence a given template without prior knowledge (de novo) of the wild type or expected sequence in conjunction with primer extension in the presence of a labeled chain terminating nucleotide.Type: GrantFiled: June 29, 2001Date of Patent: September 20, 2005Assignee: Beckman Coulter, Inc.Inventors: Steven R. Head, Philip Goelet, Jonathan Karn, Michael Boyce-Jacino
-
Patent number: 6573045Abstract: The invention relates to a solution-based assay for identifying RNA binding compounds, based on competition. The assay comprises a reporter molecule carrying a fluorescent or chromogenic group that can form a one-to-one complex with an RNA target molecule carrying a second fluorescent or chromogenic group in such a way that the two groups are in sufficient proximity for fluorescence resonance energy transfer and/or quenching to take place. Addition of a compound-to-be-tested prevents formation of the complex and thereby increases the fluorescence of the RNA target and/or reporter molecules relative to the signal obtained in the absence of the test compound. The invention also provides for quantitative screening methods and kits are also included.Type: GrantFiled: June 3, 1999Date of Patent: June 3, 2003Assignee: Ribotargets, Ltd.Inventors: Jonathan Karn, Catherine Denise Prescott
-
Publication number: 20020146704Abstract: The present invention describes a novel nucleic acid sequencing reagent which consists of a capture moiety, a spacer region and a sequence specific hybridizing region of 4-8 bases. The nucleic acid sequencing reagent of the present invention can also contain an attachment moiety. The nucleic acid sequencing reagent can be arranged into a nested array. This array configuration can then be used to sequence a given template without prior knowledge (de novo) of the wild type or expected sequence in conjunction with primer extension in the presence of a labeled chain terminating nucleotide.Type: ApplicationFiled: June 29, 2001Publication date: October 10, 2002Inventors: Steven R. Head, Philip Goelet, Jonathan Karn, Michael Boyce-Jacino
-
Publication number: 20020127543Abstract: The invention provides for compounds comprising nucleotide sequences 5′-P-N1-N2-G-N3-C-I-3′ and 3′-Q-N4-N5-N6-N7-N8-N9-Y-J-5′ that are the generic sequences of a mIRES of an HCV genome, and variants thereof The invention also provides assays that utilise the compounds of the invention, including assays for detection of HCV antiviral compounds.Type: ApplicationFiled: December 22, 2000Publication date: September 12, 2002Inventors: Jonathan Karn, Stephen Walker
-
Patent number: 6395891Abstract: The invention relates to an isolated nucleic acid comprising two operatively linked binding sites for HIV Rev protein, the sites comprising a nucleation motif and an oligomerization motif, wherein the nucleic acid binds Rev protein monomers with a higher degree of cooperativity than wild-type RRE.Type: GrantFiled: September 11, 1998Date of Patent: May 28, 2002Assignee: RiboTargets LimitedInventors: Jonathan Karn, Rodney Warren Zemmel, Peter Jonathan Gasking Butler, Roger K. Craig, Alistair Simpson Irvine
-
Patent number: 6337188Abstract: The present invention describes a novel nucleic acid sequencing reagent which consists of a capture moiety, a spacer region and a sequence specific hybridizing region of 4-8 bases. The nucleic acid sequencing reagent of the present invention can also contain an attachment moiety. The nucleic acid sequencing reagent can be arranged into a nested array. This array configuration can then be used to sequence a given template without prior knowledge (de novo) of the wild type or expected sequence in conjunction with primer extension in the presence of a labeled chain terminating nucleotide.Type: GrantFiled: August 25, 2000Date of Patent: January 8, 2002Assignee: Orchid BioSciences, Inc.Inventors: Steven R. Head, Philip Goelet, Jonathan Karn, Michael Boyce-Jacino
-
Patent number: 6322968Abstract: The present invention describes a novel nucleic acid sequencing reagent which consists of a capture moiety, a spacer region and a sequence specific hybridizing region of 4-8 bases. The nucleic acid sequencing reagent of the present invention can also contain an attachment moiety. The nucleic acid sequencing reagent can be arranged into a nested array. This array configuration can then be used to sequence a given template without prior knowledge (de novo) of the wild type or expected sequence in conjunction with primer extension in the presence of a labeled chain terminating nucleotide.Type: GrantFiled: November 21, 1997Date of Patent: November 27, 2001Assignee: Orchid BioSciences, Inc.Inventors: Steven R. Head, Philip Goelet, Jonathan Karn, Michael Boyce-Jacino
-
Patent number: 6316194Abstract: The invention provides a method for determining whether a test compound binds to a target RNA, the method comprising the steps of: (a) contacting the test compound with a pair of indicator molecules comprising an antimicrobial labelled with a donor group or an acceptor group and the target RNA labelled with a complementary acceptor or donor group, the pair being capable of binding to each other in an orientation that permits the donor group to come into sufficient proximity to the acceptor group to permit fluorescent resonance energy transfer and/or quenching to take place; and (b) measuring the fluorescence of the target RNA and/or the antimicrobial in the presence of the test compound and comparing this value to the fluorescence of a standard.Type: GrantFiled: December 16, 1999Date of Patent: November 13, 2001Assignee: RibotargetsInventors: Jonathan Karn, David Justin Charles Knowles, Alastair Iain Hamilton Murchie, Georg Friedrich Lentzen
-
Patent number: 6225045Abstract: The invention relates to an isolated nucleic acid comprising two operatively linked binding sites for HIV Rev protein, the sites comprising a nucleation motif and an oligomerization motif, wherein the nucleic acid binds Rev protein monomers with a higher degree of co-operativity than wild-type RRE.Type: GrantFiled: April 15, 1997Date of Patent: May 1, 2001Assignee: Ribotargets, Ltd.Inventors: Jonathan Karn, Rodney Warren Zemmel, Peter Jonathan Gasking Butler, Roger K. Craig, Alistair Simpson Irvine
-
Patent number: 6153382Abstract: A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding ot rev within cells. The binding sequence or sequences, by binding with rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying that inhibit rev binding.Type: GrantFiled: September 15, 1997Date of Patent: November 28, 2000Assignee: Ribotargets, Ltd.Inventors: Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall
-
Patent number: 6114109Abstract: A synthetic molecule comprises at least one oligonucleotide, comprising and RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.Type: GrantFiled: May 22, 1998Date of Patent: September 5, 2000Assignee: RiboTargets, Ltd.Inventors: Jonathan Karn, Michael J. Gait, Shaun Heaphy, Colin Dingwall
-
Patent number: 5952174Abstract: A method is provided for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule. The method involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.Type: GrantFiled: September 15, 1997Date of Patent: September 14, 1999Assignee: Orchid Biocomputer, Inc.Inventors: Theo Nikiforov, Jonathan Karn, Philip Goelet
-
Patent number: 5821046Abstract: A synthetic molecule comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.Type: GrantFiled: October 10, 1995Date of Patent: October 13, 1998Assignee: RiboTargets Holdings PLCInventors: Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall
-
Patent number: 5786145Abstract: A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding to rev within cells. The binding sequence or sequences, by binding rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying compounds that inhibit rev binding.Type: GrantFiled: October 10, 1995Date of Patent: July 28, 1998Assignee: Medical Research CouncilInventors: Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall
-
Patent number: 5679524Abstract: A method is provided for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule. The method involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.Type: GrantFiled: August 9, 1996Date of Patent: October 21, 1997Assignee: Molecular Tool, Inc.Inventors: Theo Nikiforov, Jonathan Karn, Philip Goelet